Cannabinoids are a group of chemicals derived from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and research has shown that it has anti inflammatory properties to heal animals with nervous system disorders. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychoactive effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endogenous cannabinoid system and allow cannabinoids to bind and do their job in the body. This paper will talk about anxiety and how cannabinoids can be used to treat social anxiety disorder.
Here is the full scientific article if you wish to download it.
Cannabinoids may be a therapeutic for anxiety disorders
This review delivers a report of anxiety disorders based on new completed surveys of the general population. The overall resilience of anxiety disorders is seen to be quite astronomical, but with a lot of variation from the most resilient to the least resilient syndromes. Age of onset anxiety disorders are typically common in childhood or adolescence and the course is often chronic-recurrent. Anxiety disorders are highly likely when paired with other mental disorders. Because of their early age of onset, they are often the sometimes primary syndromes when paired with mental disorders, bringing the question up whether early interventions are necessary to treat anxiety disorders and if this may have a beneficial effect on the onset or severity of secondary disorders such as mood and drug abuse syndromes. This potential has not yet been massively looked at but allows more research to take place given the high societal costs of anxiety syndromes.
Cannabinoids, a treatment for social anxiety disorder?
Although much has been understood about the pharmacotherapy of social anxiety syndrome, many areas need further study. These include studies of specific populations, such as children and adolescents, patients with drug abuse syndromes, research on the optimal sequencing of medication and psychotherapy, and longer duration efficiency research in real world situations. Much studies on the pharmacotherapy of social anxiety syndrome has been driven by huge clinical discoveries. However, there is more and more papers every day being uploaded on the neurobiology of social anxiety syndrome, and on the specific impacts of treatment on underlying neurocircuitry. Bigger data is also available on how specific genetic actions may affect not only on neurocircuitry, but also on treatment result in social anxiety syndrome. Understanding of the basic neurobiology of anxiety, and more translation of such discoveries in clinical settings, might give way to ongoing therapeutic developments.